The aim of the alliance is to provide "streamlined drug development services" - Qualia is a provider of Phase I-IV clinical research services, while Tandem is a bioanalytical and immuoanaltyical testing laboratory. "It is a true partnership: Qualia's clinical research foundation combined with Tandem's scientific knowledge, low-risk approach, and technologies," said the two contract research organisation (CROs) in a statement. "From a geographic standpoint, we are also perfectly equipped to serve our clients' needs for a completely integrated approach." Qualia's main clinic is located in the middle of the US while Tandem has facilities on the east and west coasts. Working together, the firms said they would now be able to offer clients "synchronised scheduling in order to minimize "downtime" between clinical completion and sample transfer for bioanalysis." Additionally the alliance means that clients can "effectively use the companies as one resource and maintain a single point of contact throughout all aspects of a given project," they said. Tandem has been expressing its ambition of late to expand its existing services to a new level. In September the firm acquired PharmaKD, a Massachussets-based division of Linden Technologies, in a bid to enter the market for drug metabolite identification and biomarker discovery. In recent years, new chemical entities approved by the Food and Drug Administration (FDA) have decreased mainly due to safety and toxicity issues. Nevertheless, the costs associated with developing and launching a drug to market have increased yearly. By acquiring PharmaKD, Tandem gained access to its DMDiscovery platform, a drug-metabolism technology that can increase the productivity of drug metabolite identification and quantitation.